Fully human monoclonal antibodies can be obtained through rapid screening. At present, Weilizhibo has a number of monoclonal or double antibody components screened from fully human phage display libraries. These projects have entered or are about to enter the clinical development stage.

For more complex targets such as GPCR or targets that require special functions, mouse hybridoma technology is used to ensure the diversity of candidate molecules, and the final candidate molecules (or antibodies) are obtained through mature humanization technology.

This technology is suitable for screening relatively stable and high-yield single domain antibodies.Single-domain antibodies have smaller molecular weight and better stability than traditional antibodies, and can recognize epitopes that traditional antibodies cannot.And it has better penetration and accessibility to tumor tissue and microenvironment.